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Rapid Multiplex Testing for Upper Respiratory Pathogens 
in the Emergency Department: A Randomized 
Controlled Trial
Larissa May,1 Grant Tatro,1 Eduard Poltavskiy,2 Benjamin Mooso,1 Simson Hon,1 Heejung Bang,2,3 and Christopher Polage4,5
1Department of Emergency Medicine, University of California Davis, Sacramento, California, USA, 2Graduate Group in Epidemiology, University of California Davis, Davis, California, USA, 
3Department of Public Health Sciences, University of California Davis, Davis, California, USA, 4Department of Pathology, University of California Davis, Sacramento, California, USA, and 
5Department of Pathology, Duke University, Durham, North Carolina, USA
Background. Acute upper respiratory tract infections are a common cause of emergency department (ED) visits and often result 
in unnecessary antibiotic treatment.
Methods. We conducted a randomized clinical trial to evaluate the impact of a rapid, multipathogen respiratory panel (RP) test 
vs usual care (control). Patients were eligible if they were ≥12 months old, had symptoms of upper respiratory infection or influenza-
like illness, and were not on antibiotics. The primary outcome was antibiotic prescription; secondary outcomes included antiviral 
prescription, disposition, and length of stay (ClinicalTrials.gov# NCT02957136).
Results. Of 191 patients enrolled, 93 (49%) received RP testing; 98 (51%) received usual care. Fifty-three (57%) RP and 7 (7%) 
control patients had a virus detected and reported during the ED visit (P = .0001). Twenty (22%) RP patients and 33 (34%) usual care 
patients received antibiotics during the ED visit (–12%; 95% confidence interval, –25% to 0.4%; P = .06/0.08); 9 RP patients received 
antibiotics despite having a virus detected. The magnitude of antibiotic reduction was greater in children (–19%) vs adults (–9%, post 
hoc analysis). There was no difference in antiviral use, length of stay, or disposition.
Conclusions. Rapid RP testing was associated with a trend toward decreased antibiotic use, suggesting a potential benefit from 
more rapid viral tests in the ED. Future studies should determine if specific groups are more likely to benefit from testing and eval-
uate the relative cost and effectiveness of broad testing, focused testing, and a combined diagnostic and antimicrobial stewardship 
approach.
Keywords. Upper respiratory tract infection; diagnostic test; randomized clinical trial; emergency department; antibiotic 
treatment.
Acute respiratory tract infection (ARTI) is a common cause of 
emergency department (ED) visits, accounting for ~12.6 million 
cases annually from 2001 to 2010 [1]. Many of these cases are due to 
viral infection, and up to 30%–40% are prescribed antibiotics inap-
propriately [2]. This is worrisome, as overuse of antibiotics creates 
selective pressure for antibiotic-resistant pathogens that increases 
morbidity, mortality, and health care cost for affected patients [3]. 
In addition, antibiotic use can lead to drug-related adverse reac-
tions that could prompt patients to return to the ED [3, 4].
Factors contributing to antibiotic overprescribing include 
concerns regarding patient satisfaction scores, difference in 
patient expectation and understanding of antibiotic effective-
ness for viral infections, medical liability, and diagnostic uncer-
tainty [3, 5]. The last point is especially applicable in the ED 
given the patient volume and current standard of care, where 
microbiologic testing results are often not available to inform 
diagnosis and treatment. Therefore, the ED remains a high-
priority target for rapid microbiologic testing and antimicrobial 
stewardship.
Recent improvements in molecular diagnostics and the de-
velopment of rapid, multirespiratory pathogen molecular tests 
provide an opportunity to diagnose viral ARTI with high sensi-
tivity and specificity during the ED visit and potentially improve 
patient management. Hence, we sought to evaluate whether 
having a rapid, multipathogen test result available during the 
ED visit would have a significant impact on management and 
outcomes in patients with clinical signs and symptoms of ARTI.
METHODS
Study Design
We conducted a prospective, patient-oriented, pilot randomized 
clinical trial of rapid multiplex respiratory pathogen testing (RP 
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test group) vs usual care (usual care or control group) in a level 
1 emergency department with limited use of single-organism 
rapid point-of-care tests at a quaternary referral medical center. 
The study began in December 2016 and occurred over 2 winter 
respiratory seasons and 1 intervening nonrespiratory  season. 
Patients were eligible if they were age 1 or older and being 
evaluated for influenza-like illness (ILI; fever or cough and sore 
throat) or upper respiratory infection (URI; nonspecific upper 
respiratory symptoms without fever). Patients were excluded if 
they were already on antibiotics at the time of ED presentation, 
not English- or Spanish-speaking, cognitively impaired with no 
legally authorized representative, or expected to leave before 
multiplex test results were available. If a patient was deemed eli-
gible for the study, the treating provider was approached by a re-
search team member to confirm that URI or ILI was suspected, 
and the patient was expected to be present for at least the next 
90 minutes. Patients were recruited Monday through Friday be-
tween 8 am and 10 pm from rapid care and main adult and pe-
diatric ED areas. Screening was performed under a waiver of 
informed consent, and the study protocol was approved by the 
UC Davis Institutional Review Board.
After informed consent, a patient questionnaire was admin-
istered by a trained research assistant to collect demographic 
information and medical history (Supplementary Data). 
Information about the patient’s medical history and current 
medications was reviewed in the electronic health record (EHR) 
and discussed with the patient. Patients were specifically asked 
if they had chronic medical conditions, if they had medical con-
ditions affecting their immune system (HIV, diabetes, cancer, 
liver disease, kidney disease, or dialysis, or if they were on im-
munosuppressive medications such as steroids), and if they were 
currently taking any medications. Subjects were randomized 
to either rapid near point-of-care multirespiratory pathogen 
molecular testing (FilmArray Respiratory Panel, BioFire) plus 
clinician-directed usual care or usual care alone. This included 
but was not limited to no testing, targeted influenza and/or res-
piratory syncytial virus (RSV) point-of-care testing (Quidel Flu 
A/B or RSV before January 10, 2018, then Roche Liat Influenza 
A/B or RSV), rapid point-of-care testing for streptococcal 
pharyngitis (Acceava Strep A  test before January 2018, then 
Roche Liat), or multirespiratory pathogen panel testing (xTAG 
Respiratory Viral Panel, Luminex before December 2017, then 
GenMark ePlex) performed at an off-site laboratory 3–4 times 
weekly in scheduled daytime batches.
Simple randomization was used with a computer-generated 
randomized list to allocate subjects to the intervention or con-
trol arms of the study, and sealed, opaque envelopes were used 
to blind research staff to allocation up until written consent 
was completed. Clinicians and patients were not blinded to 
the testing done, and usual care proceeded in both arms. After 
randomization, patients in the interventional arm had a naso-
pharyngeal swab specimen collected by a nurse or clinician. 
This specimen was transported via a tube system to an onsite 
clinical laboratory (upstairs), where the FilmArray Respiratory 
Panel was performed in real time, with the goal of results re-
ported in the EHR within 2 hours. Clinicians were informed 
that results of the patient’s rapid molecular testing would be 
returned through the patient’s EHR, and they received an au-
tomatic in-basket message through the EHR as well as a noti-
fication by the research coordinator or research assistant when 
results were back.
Data Collection and Outcomes
Follow-up treatment and outcome data were abstracted 
from each subject’s EHR by a trained research staff member. 
Abstracted data included medical history, clinical signs and 
symptoms, demographics, lab and radiology results, medica-
tions (including asthma, diabetes, chemotherapy, immuno-
suppressive, antibiotic, and antiviral medications), ED/hospital 
course, length of ED/hospital stay, clinician diagnoses from the 
index encounter, and limited review of subsequent encoun-
ters to identify deaths and 30-day revisits to the ED study site 
for similar complaints. Up to 3 return visits were recorded, 
and each was categorized as either “respiratory illness” or 
“nonrespiratory illness” according to the primary diagnoses of 
the encounter. In the case of patients who returned to the ED 
but left before being treated, their chief complaint was used in-
stead of their diagnosis. Chest x-ray results were reviewed by a 
clinical investigator (L.S.M.) to identify patients with imaging 
consistent with bacterial pneumonia or viral pattern illness.
The primary outcome was antibiotic administration or 
prescription in the ED by an emergency medicine clinician. 
Secondary outcomes included the proportion of patients with 
a respiratory pathogen identified by the FilmArray Respiratory 
Panel test or any other upper respiratory pathogen diagnostic 
test ordered by the physician; the proportion of patients with 
a laboratory-confirmed influenza diagnosis; the proportion of 
patients receiving appropriate anti-influenza treatment or pre-
scription in the ED by an emergency medicine clinician (com-
posite rate of anti-influenza treatment in positive patients and 
nonuse of anti-influenza treatment in negative patients); the 
proportion of patients discharged home from the ED vs hospital 
admission; the proportion of patients with all-cause or respira-
tory illness–related repeat ED visit, hospital or ICU admission, 
or death within 30 days; clinician adherence to guidelines for 
the treatment of patients with influenza (recommendations for 
use of antivirals only); length of ED stay; length of hospital stay; 
time to influenza test results; and time to other respiratory path-
ogen test results.
Statistical Analyses
We summarized data by standard descriptive statistics: contin-
uous variables by mean and standard deviation (SD) or median 
and range (= min–max), categorical variables by frequency and 
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percentage. We analyzed the equality of the proportions for bi-
nary outcomes with the chi-square or Fisher exact test, as ap-
propriate (eg, cell count <5), and reported (2-sided) P values, 
unadjusted for multiple testing. We also computed the differ-
ence in event rates (ie, proportion) and the associated 95% con-
fidence interval (CI). For continuous outcomes, the Wilcoxon 
test was used for comparison. We also performed a post hoc 
stratified analysis for antibiotic use (primary outcome), anti-
viral use, and discharge status, based on the patient’s age (eg, 
adult vs pediatric) for exploratory purposes. We analyzed the 
data based on the (modified) intent-to-treat principle; that is, 
we analyzed all patients as randomized, excluding early drop-
outs with outcomes data unavailable. We used SAS, version 9.4 
(SAS Institute, Cary, NC, USA), for data analysis.
RESULTS
The study was initiated in December 2016 with a target enroll-
ment of 325 participants over 12 months, based on a power cal-
culation that 304 patients (152 in each arm) would have 80% 
power to detect a 15% difference in antibiotic prescription be-
tween arms. The study was stopped in April 2018 (17 months) 
due to budgetary constraints. Our study enrolled 191 patients, 
with 93 (48.7%) randomized to the interventional RP test group 
and 98 (51.3%) randomized to the usual care control group 
(Figure 1). There was no statistically significant difference in 
age, race, or existence of a chronic medical condition between 
the 2 groups. The complete baseline characteristics of the study 
participants are summarized in Table 1.
In the RP test group, 53 (57%) patients had 1 or more viruses 
detected and reported during the ED visit; 8 (9%) additional 
RP patients had a positive virus result reported after the ED 
visit (Table 2). In the control group, 7 (7%) patients had a virus 
detected and reported by existing single-organism tests during 
the ED visit, and an additional 13 (14%) patients had a virus 
detected via the off-site laboratory multirespiratory pathogen 
panel after the ED visit. The results from the rapid RP tests were 
available in <2 hours on average (Table 2).
The primary and secondary outcome results are shown in 
Table 3. Twenty patients received antibiotics in the RP test group 
(20 of 93 [22%]), including 9 patients with a virus detected (9 of 
61 [15%]), whereas 33 patients received antibiotics in the usual 
care control arm (33 of 98 [34%]), including 9 patients (9 of 20 
[45%]) with a virus detected (–12% antibiotic treatment differ-
ence; 95% CI, –25% to +0.4%; P = .061/0.075, chi-square/Fisher 
exact test). Most RP test group patients who received antibiotics 
despite having virus detected either had a concomitant bacterial 
infection diagnosed clinically (8 of 9 [89%]) or were discharged 
before RP results were available (3 of 9 [33%]). There was no statis-
tically significant difference in antiviral use between the 2 groups 
(P = .53). For testing, 8 RP test group patients (8 of 93 [9%]) had 
a rapid single-organism test performed (all influenza) in addition 
to the interventional RP test, and 18 of 98 (18%) control patients 
had a rapid single-organism test performed in the ED (16 patients 
Assessed for Eligibility (n = 2435)
Randomized (n = 194)
Allocated to BioFire FilmArray
Respiratory Viral Panel (n = 95)
Allocated to Standard of  Care
(n = 99)
Withdrew from Study (n = 2) Withdrew from Study (n = 1)
Received BioFire RVP Test
(n = 93)
Analyzed (n = 93) Analyzed (n = 98)
Analysis
Allocation
Enrollment
Excluded (n = 2241)
• Ineligible (n = 1946)
• Declined to Participate (n = 259)
• Missed (n = 36)
Figure 1. CONSORT diagram.
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with rapid influenza test alone, 2 patients with rapid influenza and 
rapid RSV test), and 24 of 98 (24%) had an off-site respiratory 
panel performed with results delivered after the ED visit (24 of 37 
[65%] total control patients with any respiratory viral test). There 
was no significant difference in length of ED stay, disposition from 
the ED, or hospital stay among admitted patients between the 2 
groups. Seven control patients were admitted to the ICU (7 of 98 
[7%]) vs 0 of 93 (0%) in the RP test group. Supplementary Table 1 
provides clinical data for these 7 control patients. In the post hoc 
analysis stratified by age, 3 of 32 (9%) pediatric patients received 
antibiotics in the RP test group vs 11 of 39 (28%) in the usual care 
control group (–19% antibiotic treatment difference; 95% CI, 
–36% to –1%; P = .047/0.07, chi-square/Fisher exact test) (Table 
4). There were no other outcome differences between groups in 
the post hoc stratified age analysis (Table 4).
DISCUSSION
Large molecular panels capable of detecting 10–20 respiratory 
viruses simultaneously have been available for >10  years, but 
the utility of detecting noninfluenza, non-RSV viruses in out-
patients is debated because results are delayed, and therapy does 
not exist [6]. Meanwhile, diagnostic advances have made it pos-
sible to get results within 1–2 hours, and reducing unnecessary 
antibiotic use has become a national priority [7].
The FilmArray Respiratory Panel provides results for 20 
different respiratory pathogens in approximately 1 hour with 
85%–100% sensitivity and 90%–100% specificity [8]. However, 
Table 2. Diagnostic Testing and Pathogens Detected in Patientsa
RP Test Group  
Intervention 
(n = 93)
Usual Care  
Group Control 
(n = 98)
Lab-confirmed pathogensb, No. (%)   
 ≥1 viruses 61 (66) 20 (20)
  Reported during ED visit 53 (57) 7 (7)
  Reported after ED visit 8 (9) 13 (13)
 Influenza (any strain) 24 (26) 8 (8)
 RSV 12 (13) 3 (3)
 Rhinovirus/enterovirus 14 (15) 7 (7)
 Noninfluenza, non-RSV virus 32 (34) 9 (9)
 ≥1 bacteria 0 (0) 1 (1)
BioFire processing time,  
mean ± SD, median, range, h
1.73 ± 0.39, 1.68,  
0.08–2.96 (n = 92)c
N/A
Ancillary testing, No. (%)   
 Chest x-ray 64 (69) 70 (71)
  Bacterial pneumonia 10 (11) 17 (17)
  Viral pattern illness 14 (15) 10 (10)
 POC rapid influenza 8 (9) 18 (18)
  Positive 1 (1) 5 (5)
 POC RSV 0 (0) 2 (2)
  Positive 0 (0) 2 (2)
 POC rapid strep 9 (10) 2 (2)
  Positive 0 (0) 1 (1)
 Off-site respiratory viral panel 1 (1) 24 (24)
  Positive 1 (1) 15 (15)
Abbreviations: ED, emergency department; POC, point of care; RP, respiratory panel; RSV, 
respiratory syncytial virus.
aNumbers and percentages reflect intention-to-treat analysis of full study arm group in all 
rows.
bAll pathogens detected by rapid multiplex testing included influenza A (n = 1), influenza 
A subtype H1 2009 (n = 2), influenza A subtype H3 (n = 17), influenza B (n = 4), rhinovirus/
enterovirus (n = 14), respiratory syncytial virus (n = 12), metapneumovirus (n = 6), adeno-
virus (n = 3), coronavirus OC43 (n = 3), coronavirus HKU1 (n = 2), coronavirus NL63 (n = 2), 
coronavirus 229E (n = 1), parainfluenza 2 (n = 2), and parainfluenza 3 (n = 1).
cOne subject did not have a recorded collection time. No “processing time” could be 
calculated.
Table 1. Patient Characteristics
RP Test Group  
Intervention 
(n = 93)
Usual Care  
Group Control 
(n = 98)
Age, mean ± SD, median, 
range, y
29 ± 23, 26, 1–89 29 ± 25, 23, 1–84
Age category, No. (%)   
Pediatric (1–17 y) 32 (34) 39 (40)
Adult (≥18 y) 61 (66) 59 (60)
Race, No. (%)   
 White 43 (46) 44 (45)
 Black or African American 18 (19) 17 (17)
 American Indian/Alaska native 5 (5) 1 (1)
 Asian 3 (3) 5 (5)
 Native Hawaiian/Pacific  
Islander
2 (2) 2 (2)
 Other/mixed 20 (22) 29 (30)
 No response 2 (2) 0 (0)
Ethnicity, No. (%)   
 Hispanic or Latino 27 (29) 32 (33)
 Not Hispanic or Latino 66 (71) 66 (67)
BMI, mean ± SD, median,  
range (adults only), kg/m2
31.4 ± 9.3, 30.1,  
16.3–61.7 (n = 49)a
29.7 ± 7.5, 28.4,  
18.3–52.0 (n = 53)a
BMI >40 kg/m2, No. (%) 8 (9) 4 (4)
Active smoking, No. (%) 15 (16) 13 (13)
Recent sick contacts, No. (%) 53 (57) 57 (58)
Influenza vaccination in last year, 
No. (%)
40 (43) 38 (39)
Chronic medical conditions, 
No. (%)
  
 Neurological/ 
neurodevelopmental
9 (10) 9 (9)
 Chronic lung disease 25 (27) 40 (41)
  Asthma 22 (24) 33 (34)
  COPD 4 (4) 8 (8)
 Heart disorders 23 (25) 24 (24)
  CHF 7 (8) 3 (3)
  Other 20 (22) 24 (24)
 Blood disorders 3 (3) 2 (2)
 Endocrine/metabolic  
disorders
13 (14) 17 (17)
  Diabetes mellitus 9 (10) 9 (9)
  Other 6 (6) 12 (12)
 Kidney disorders 3 (3) 6 (6)
 Liver disorders 5 (5) 3 (3)
 Immunosuppressed 17 (18) 17 (17)
Abbreviations: BMI, body mass index; CHF, congestive heart failure; COPD, chronic ob-
structive pulmonary disease; RP, respiratory panel. 
aMissing BMI measurements due to lack of height measurements for some patients.
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these large, multipathogen tests are more expensive than tar-
geted point-of-care tests, and the clinical utility has not been 
rigorously evaluated, especially in the ED. As a result, some 
payers are currently moving to limit utilization and reimburse-
ment of large multipathogen panels in favor of targeted influ-
enza and/or RSV testing [9]. This evidence gap in utility and 
reimbursement uncertainty create challenges for clinicians, la-
boratories, and hospitals in justifying the cost of instruments 
and tests, and there is a lack of guidance regarding optimal use. 
We hypothesized that rapid multirespiratory pathogen testing 
with results reported during the ED visit could alter treatment 
in the early phases of patient care and potentially impact patient 
and health care outcomes.
Thus, we conducted a randomized clinical trial of the 
FilmArray RP vs usual care in ED patients with signs or symp-
toms of upper respiratory infection or influenza-like illness. 
The primary outcome was antibiotic prescription. The trial 
was stopped after 17 months before reaching the prespecified 
sample size due to dwindling funds and slow enrollment. 
However, there was a trend toward decreased antibiotic use 
with RP testing (–12% difference; P  =  .06/0.08, chi-square/
Fisher exact test) that was larger in pediatric patients (–19% 
difference; P  =  .047/0.07) in an age-stratified post hoc anal-
ysis, suggesting a potential benefit of increased rapid RP testing 
in some ED patients. Antiviral prescription (ie, oseltamivir) 
was not significantly affected despite a 3-fold increase in viral 
(66% vs 20%) and influenza detections (26% vs 8%), perhaps 
due to the lack of guidance regarding antiviral use in our study. 
Other secondary outcomes, such as ED disposition, 30-day re-
turn visits, and 30-day deaths, did not differ between groups. 
Thus, the main effects of rapid RP testing in this study were to 
increase the proportion of patients with a lab-confirmed viral 
detection for clinical decision-making by 3-fold and reduce an-
tibiotic prescription by about one-third. It is unknown if similar 
benefits could be achieved with targeted testing for influenza 
and/or RSV or antimicrobial stewardship alone. However, it has 
Table 3. Primary and Secondary Outcomesa
RP Test Group Intervention 
(n = 93)
Usual Care Group Control  
(n = 98)
Differenceb (95% CI) 
P value
Medications prescribed in ED, No. (%)    
 Antibiotics 20 (22) 33 (34) –12% (–25% to +0.4%) 0.06/0.08
 Antivirals 9 (10) 7 (7) +3% (–5% to –10%) 0.53/0.61
Adherence to antiviral guidelines, No. (%)    
 Given oseltamivir (overall) 9 (10) 7 (7)  
 Adherence to guidelines (overall) 73 (78) 90 (92)  
 Influenza-positive (lab-confirmed) 24 (26) 8 (8)  
  Given oseltamivir 7/24 (29) 3/8 (38)  
  Adhered to guidelines 7/24 (29) 3/8 (38)  
 Influenza-negative (lab-confirmed) 69 (74) 29 (30)  
  Given oseltamivir 2/69 (3) 0/29 (0)  
  Adhered to guidelines 66/69 (96) 29/29 (100)  
ED disposition    
 Discharged from ED, No. (%) 69 (74) 66 (67) NS
  Length of ED stay, mean ± SD, median, range, h 5.4 ± 2.5, 4.7, 1.5–15.2 5.3 ± 2.4, 5.0, 1.6–13.1 NS
 Admitted to hospital, No. (%) 20 (22) 27 (28) NS
  General inpatient, No. (%) 20 (22) 20 (20) NS
  Length of hospital stay, mean ± SD, median, range, h 92.7 ± 95.6, 71.2, 23.8–441 77.0 ± 60.7, 56.1, 5.4–227.6 NS
 ICU, No. (%) 0 (0) 7 (7)  
  Length of hospital stay, mean ± SD, median, range, h N/A 114.2 ± 110.8, 54.9, 44.3–343.3  
 Left against medical advice, No. (%) 4 (4) 4 (4)  
 Other, No. (%) 0 (0) 1 (1)  
Return ED visit ≤30 d, No. (%) 16 (17) 16 (16)  
 Respiratory illnessc 8 (9) 5 (5)  
 Nonrespiratory illness 8 (9) 11 (11)  
Death ≤30 d, No. (%) 1 (1) 0 (0)  
 Respiratory illness 0 (0) 0 (0)  
 Nonrespiratory illness 1 (1) 0 (0)  
Abbreviations: CI, confidence interval; ED, emergency department; ICU, intensive care unit; NS, nonsignificant; RP, respiratory panel.
aNumbers and percentages reflect intention-to-treat analysis of full study arm group, except where subgroup denominator is noted.
bFor primary and secondary outcomes only.
cAdditional index ED visit information for patients with 30-day return ED visit for respiratory illness: RP test group (n = 8; 2 pediatric, 6 adults): 8 chest x-rays performed (5 normal, 3 ab-
normal), 8 tested (4 virus detected, 4 all negative, 0 bacteria detected), 2 prescribed antibiotics, 1 prescribed antiviral; usual care group (n = 5; 5 adults): 4 chest x-rays performed (3 normal, 
1 abnormal), 1 RVP tested = all negative, 0 prescribed antibiotics, 0 prescribed antivirals.
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been suggested that influenza testing alone may be sufficient 
and cost-effective when applied to outpatients, given that other 
viruses do not have any specific treatment at this time [9]. Other 
potential benefits of rapid RP testing, such as infection preven-
tion and patient satisfaction, were not investigated.
Relatively few other studies have investigated the effect of 
large respiratory panels on outcomes, and no prior random-
ized controlled trials have been performed in US ED patients 
to our knowledge. A recent trial in an Argentinian ED found 
reduced antibiotic and antiviral initiation in patients receiving 
the FilmArray assay vs standard testing; this study was better 
powered (432 patients) than our study but may not be gen-
eralizable to the United States as empiric treatment without 
testing is more common in this country [10, 11]. In a retro-
spective analysis by Rogers et al., the BioFire FilmArray was 
associated with decreased duration of antibiotic use, length of 
hospital stay, and length of isolation in children admitted to 
the hospital with ARTI [12]. Future investigations with more 
targeted use of rapid multiplex testing in the ED could yield 
more promising results, but additional research is needed to 
determine which patients would benefit most from testing. 
For example, Xu et  al. showed that the FilmArray could be 
cost-effective when replacing off-site direct fluorescence 
antibody testing in pediatric ED patients [13]. A recent ran-
domized controlled trial from the United Kingdom found 
an increase in patients with short courses of antibiotics and 
a 1-day reduction in length of stay in patients with rapid RP 
testing but did not see a difference in the overall proportion 
of antibiotic treatment compared with the control arm [14]. 
However, this study was done outside the United States and 
included patients outside the ED, so the results may not be 
directly comparable to our study.
Our patients came from a heterogeneous ED patient popu-
lation and included a wide range of individuals with ARTI an-
ywhere on providers’ differential diagnosis; in hindsight, this 
may not have been the ideal population, as clinicians would not 
necessarily have ordered rapid multiplex testing on these pa-
tients and may have been less likely to modify their behavior 
in response to the results. However, the high rate of chest x-ray 
testing in our study (~70%, both study arms) suggests that pro-
viders were at least considering a respiratory illness in most pa-
tients but may not have been in the habit of relying on viral 
testing for their clinical decision-making.
Another interpretation of our results is that while multiplex 
testing does well identifying influenza and other URI-causing 
viruses in the ED, implementation alone was not sufficient 
to significantly influence clinician decision-making and pa-
tient outcomes. For example, influenza testing alone may be 
enough for clinical decision-making during influenza season 
[9]. It is likely that a thoughtful and comprehensive steward-
ship program around rapid diagnostics could be required to 
lead to meaningful changes in outcomes. It is also possible that 
deploying rapid diagnostic tools would lead to more significant 
changes if applied to an area that has higher baseline antibiotic 
prescription rates such as an urgent care setting.
Shortening the 90-minute turnaround time (TAT) of the 
BioFire FilmArray Respiratory Panel might also be neces-
sary for this test to be effective in the ED setting. Although 
the current test was much faster than the off-site respiratory 
viral panel used at our facility, it is still not fast enough to 
match the fast-paced workflow of many EDs. Andrews et  al. 
also encountered problems with TAT in their point-of-care 
(POC) implementation of the FilmArray [6]. However, these 
problems were mainly attributed to staff availability to run 
the test after consenting subjects. The FilmArray itself was re-
ported by them to run in 65 minutes in the POC setting. If the 
FilmArray could be implemented into the ED as a POC test 
in a way that would fit seamlessly into ED workflow, the TAT 
may have been minimized for this assay, and we may have seen 
more promising results. This was demonstrated in the post hoc 
analysis by Brendish et al. on their randomized controlled trial 
in the UK. Significant improvements to outcomes, including 
antibiotic treatment and duration of antibiotics, were seen in 
patients with virus-positive RP testing that achieved a TAT 
of ≤1.6 hours vs those of >1.6 hours [15]. In this regard, it is 
Table 4. Post Hoc Subgroup Analyses
RP Test 
Group
 Intervention
 (n = 93), 
 No. (%)
Usual Care 
Group 
Control 
(n = 98),  
No. (%) Difference, %
Antibiotics prescribed in the ED   
 Overall 20/93 (22) 33/98 (34) –12
  Pediatric 3/32 (9) 11/39 (28) –19
  Adult 17/61 (28) 22/59 (37) –9
 Any virus 9/61 (15) 9/20 (45)  
 Pediatric 3/26 (12) 5/10 (50)  
 Adult 6/35 (17) 4/10 (40)  
 Influenza 3/24 (13) 2/8 (25)  
 Pediatric 1/8 (13) 1/2 (50)  
 Adult 2/16 (13) 1/6 (17)  
 RSV 1/12 (8) 2/3 (67)  
  Pediatric 1/8 (13) 1/2 (50)  
  Adult 0/4 (0) 1/1 (100)  
 Other virus 5/32 (16) 5/9 (56)  
  Pediatric 1/12 (8) 3/6 (50)  
  Adult 4/20 (20) 2/3 (67)  
Antivirals prescribed in the ED   
 Overall 9/93 (10) 7/98 (7) +3
  Pediatric 3/32 (9) 2/39 (5) +4
  Adult 6/61 (10) 5/59 (8) +2
ED disposition    
 Pediatric admits 8/32 (25) 11/39 (28) –3
 Adult admits 12/61 (20) 16/59 (27) –7
Abbreviations: ED, emergency department; RP, respiratory panel; RSV, respiratory syncy-
tial virus.
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encouraging to see newer POC nucleic acid amplification tests 
for influenza and RSV coming to market with shorter TATs, on 
the order of 10–20 minutes [16].
It is also possible that the pathogens detected do not pro-
vide sufficient information for clinicians to reduce antibiotics. 
The recently FDA-cleared BioFire FilmArray Pneumonia 
Panel will identify a wider range of respiratory bacteria and 
viruses. Depending on TAT and ability to fit into ED work-
flow, a test such as this could help reduce diagnostic uncer-
tainty when lower respiratory tract infections are also part of 
the differential diagnosis. However, detecting more pathogens 
may not be the answer. As a result of the recent Palmetto GBA 
decision, Medicare will no longer provide coverage for large 
(≥6-target) multiplexed diagnostic viral panels such as the 
BioFire FilmArray for outpatients unless policy changes in the 
future [17]. This decision to cover only 3–5 respiratory path-
ogen targets and limit their use to infectious disease clinicians 
except in the case of urgent care, ED, and inpatient settings 
highlights the importance of implementation and evaluation 
of diagnostic tests in the context of a value-based health care 
system. Simply providing test results without consideration of 
the behavioral aspects of antimicrobial prescribing may result 
in lack of clinical utility, when these tests could be beneficial 
if paired with behavioral economics strategies or as part of a 
comprehensive stewardship program to reduce inappropriate 
antibiotic use.
This study was limited by a small sample size, which most 
likely did not provide enough power to see a significant differ-
ence in outcomes, as suggested by the wide confidence inter-
vals we observed. The subjects themselves were selected based 
on symptoms, rather than a clinical decision to order multiplex 
testing. This in turn led to a heterogeneous subject population, 
many of whom might not be expected to benefit from viral 
testing. Locating a specific target population for rapid multiplex 
testing in the ED may be necessary for significant differences in 
outcomes. Finally, during the 2017–2018 influenza season, ac-
tivities were undertaken to reduce inappropriate prescribing for 
viral respiratory infections in otherwise healthy patients using 
patient and provider education, provider public commitment 
to reducing inappropriate antibiotic use, and peer comparison 
data. Thus, our already low prescribing rate may have been re-
duced, and this may have compounded our loss of power from 
underenrollment by decreasing the difference between the RP 
and usual care groups that we anticipated when we powered 
the study. We also did not analyze cost-effectiveness, and more 
research is needed to determine if multiplex testing can be ec-
onomically feasible in the ED. Finally, it is likely that use of 
comprehensive stewardship strategies and guidelines could 
have improved effectiveness beyond simple introduction of 
rapid diagnostic tests.
There were also several strengths to this study, including the rig-
orous experimental study design, relatively rapid TAT given the 
current state of the art, and generation of preliminary data for future 
more rigorous multicenter clinical trials evaluating the implementa-
tion of rapid respiratory panels in EDs and other acute care settings.
In summary, this randomized controlled trial aimed to eval-
uate the impact of rapid multiplex respiratory panel testing in 
the ED for patients with concern for acute respiratory tract in-
fection. Although our study lacked the power to see significant 
differences in outcomes, we did observe a trend in decreased 
antibiotic use for those who received multiplex testing vs the 
standard of care. Further evaluation of rapid multiplex testing in 
the ED could see changes in outcomes if the limitations of this 
study were addressed. This mainly includes identifying the right 
patient population where testing can alter patient care (vs tar-
geted testing or no testing) and focusing on implementing com-
prehensive stewardship strategies alongside diagnostic tools to 
ensure that testing is utilized appropriately and effectively.
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